Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: A study based on NSABP protocol B-24

Journal of Clinical Oncology

Volumn 30, Issue 12, 2012, Pages 1268-1273

  Allred, D Craig ^a,d   Anderson, Stewart J ^a,b   Paik, Soonmyung ^a   Wickerham, D Lawrence ^a,c   Nagtegaal, Iris D ^e   Swain, Sandra M ^a,f   Mamounas, Elefetherios P ^g   Julian, Thomas B ^a,c   Geyer, Charles E ^a,c   Costantino, Joseph P ^a,b   Land, Stephanie R ^a,b   Wolmark, Norman ^a,c  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f WASHINGTON CANCER INSTITUTE   (United States)

^g Altman Hospital Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; ADJUVANT CHEMOTHERAPY; AGE; AGED; BREAST TUMOR; CANCER STAGING; CARCINOMA IN SITU; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK ASSESSMENT; SEGMENTAL MASTECTOMY; SURVIVAL; TUMOR RECURRENCE; UNITED STATES;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAMOXIFEN; UNITED STATES;

EID: 84862247584     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.0141     Document Type: Article

References (45)

1. Bloodgood JC: Comedo carcinoma or comedo-adenoma of the female breast. Am J Cancer 22:842-853, 1934
2. Cheatle GL, Cutler M: Malignant epithelial neoplasia: Carcinoma-The precancerous or potentially carcinomatous state, in Cheatle GL, Cutler M (eds): Tumours of the Breast. Philadelphia, PA, Lippincott, 1926, pp 161-332
3. Ernster VL, Barclay J: Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: A dilemma. Natl Cancer Inst Monogr 22:151-156, 1997
4. Silverstein MJ: Ductal carcinoma in situ of the breast. Annu Rev Med 51:17-32, 2000
5. Weaver DL, Rosenberg RD, Barlow WE, et al: Pathologic findings from the Breast Cancer Surveillance Consortium: Population-based outcomes in women undergoing biopsy after screening mammography. Cancer 106:732-742, 2006 (Pubitemid 43238438)
6. Kerlikowske K: Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr 41:139-141, 2010
7. Cutuli B, Cohen-Solal-Le Nir C, De Lafontan B, et al: Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients. Eur J Cancer 37:2365-2372, 2001 (Pubitemid 33097472)
8. Nakhlis F, Morrow M: Ductal carcinoma in situ. Surg Clin North Am 83:821-839, 2003 (Pubitemid 36841912)
9. Burstein HJ, Polyak K, Wong JS, et al: Ductal carcinoma in situ of the breast. N Engl J Med 350:1430-1441, 2004 (Pubitemid 38419997)
10. Silverstein MJ, Lagios MD, Recht A, et al: Image-detected breast cancer: State of the art diagnosis and treatment. J Am Coll Surg 201:586-597, 2005 (Pubitemid 41393082)
11. Virnig BA, Tuttle TM, Shamliyan T, et al: Ductal carcinoma in situ of the breast: A systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 102:170-178, 2010
12. Hetelekidis S, Collins L, Silver B, et al: Predictors of local recurrence following excision alone for ductal carcinoma in situ. Cancer 85:427-431, 1999 (Pubitemid 29051298)
13. Horst KC, Smitt MC, Goffinet DR, et al: Predictors of local recurrence after breast-conservation therapy. Clin Breast Cancer 5:425-438, 2005
14. Millar EK, Leong AS: Significance and assessment of margin status in ductal carcinoma in situ of the breast. Adv Anat Pathol 8:338-344, 2001
15. Meijnen P, Gilhuijs KG, Rutgers EJ: The effect of margins on the clinical management of ductal carcinoma in situ of the breast. J Surg Oncol 98:579-584, 2008
16. Schnitt SJ: Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics. J Natl Cancer Inst Monogr 2010:158-161, 2010
17. Kane RL, Virnig BA, Shamliyan T, et al: The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010:130-133, 2010
18. Silverstein MJ, Barth A, Poller DN, et al: Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 31A:1425-1427, 1995
19. Solin LJ: The impact of adding radiation treatment after breast conservation surgery for ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010:187-192, 2010
20. Fisher B, Costantino J, Redmond C, et al: Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 328:1581-1586, 1993 (Pubitemid 23151917)
21. Fisher B, Dignam J, Wolmark N, et al: Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441-452, 1998 (Pubitemid 28135585)
22. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989 (Pubitemid 19062522)
23. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen for lymph nodenegative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684-690, 2001 (Pubitemid 32492809)
24. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993-2000, 1999 (Pubitemid 29271743)
25. Cuzick J, Sestak I, Pinder SE, et al: Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: Long-term results from the UK/ANZ DCIS trial. Lancet Oncol 12:21-29, 2011
26. Jordan VC: Third Annual William L. McGuire Memorial Lecture: "Studies on the estrogen receptor in breast cancer"-20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36:267-285, 1995
27. Elledge RM, Green S, Pugh R, et al: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 89:111-117, 2000 (Pubitemid 30185917)
28. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999 (Pubitemid 29220854)
29. Love RR, Duc NB, Allred DC, et al: Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 20:2559-2566, 2002 (Pubitemid 34525744)
30. Mohsin SK, Weiss H, Havighurst T, et al: Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study. Mod Pathol 17:1545-1554, 2004 (Pubitemid 39627082)
31. Feller W: An Introduction to Probability Theory and Its Applications Volume I (ed 2). New York, NY, John Wiley and Sons, 1964
32. Gail M, Simon R: Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 41:361-372, 1985
33. Gaynor JJ, Feuer EJ, Tan CC, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
34. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
35. Kalbfleisch JP, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley and Sons, 1980
36. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1727, 2005
37. Houghton J, George WD, Cuzick J, et al: Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomised controlled trial. Lancet 362:95-102, 2003 (Pubitemid 36831018)
38. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652-1662, 2005 (Pubitemid 41672231)
39. Fuqua SAW, Schiff S: The biology of estrogen receptors, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast. Philadelphia, PA, Lippincott Williams and Wilkins, 2004, pp 585-602
40. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48-e72, 2010
41. Allred DC: Commentary: Hormone receptor testing in breast cancer-A distress signal from Canada. Oncologist 13:1134-1136, 2008
42. Gown AM: Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21:S8-S15, 2008 (suppl 2)
43. Hede K: Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J Natl Cancer Inst 100:836-837, 844, 2008
44. Mathews AW: Bad cancer tests drawing scrutiny. The Wall Street Journal, January 4, 2008:B1-B2
45. Allred DC, Carlson RW, Berry DA, et al: NCCN Task Force report: Estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw 7:S1-S21; quiz S22-S23, 2009 (suppl 6)